Fortimedix has been acquired by Medtronic
Fortimedix Surgical has been successfully acquired by Medtronic (NYSE: MDT). Following the transaction, Fortimedix will operate as Medtronic Articulating Technologies.
Located at the Brightlands Chemelot Campus in Geleen, the Netherlands, Fortimedix operates a fully equipped R&D and pilot manufacturing facility that allows the seamless integration of product development and pilot manufacturing under a single roof.
Oaklins’ team in the Netherlands acted as the exclusive sell-side M&A advisor to Fortimedix in its sale to Medtronic. This transaction underscores Oaklins’ strong international track record in the medical technology sector, demonstrating their ability to unlock significant value in a rapidly evolving, innovation-driven industry. Leveraging deep sector expertise and a global network of strategic buyers, the team ensured a smooth and successful transaction process for all parties involved.
Wout Bijker
CEO, Fortimedix Surgical
Sprechen Sie mit dem Deal Team
Robbert Bon
Oaklins Netherlands
Transaktionen
Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
Mehr erfahrenRare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Mehr erfahrenDie Lindenhofgruppe veräussert ihre Mehrheitsbeteiligung an der LabPoint an Affidea Switzerland
Die LabPoint Medizinische Laboratorien AG wurde von Affidea Switzerland AG übernommen. Mit Affidea hat die Lindenhofgruppe AG einen starken strategischen Partner für die Weiterentwicklung der LabPoint gewonnen. Die Lindenhofgruppe bleibt bedeutende Aktionärin und Grosskundin des Unternehmens. Damit schafft sie die Grundlage für eine nachhaltige Weiterentwicklung von LabPoint unter einer neuen Ankeraktionärin. LabPoint soll ihre Position in der Labordiagnostik weiter stärken und gezielt ausbauen.
Mehr erfahren